SNDX

12.29

6.79% -0.895

Handel nachbörslich: 12.28 -0.005 -0.04%

Syndax Pharmaceuticals Inc (SNDX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.18

Offen:

$12.85

24-Stunden-Volumen:

2.50M

Relative Volume:

1.24

Marktkapitalisierung:

$1.18B

Einnahmen:

$139.71M

Nettoeinkommen (Verlust:

$-209.36M

KGV:

-4.1503

EPS:

-2.96

Netto-Cashflow:

$-160.60M

1W Leistung:

-10.52%

1M Leistung:

-21.45%

6M Leistung:

-36.18%

1J Leistung:

-48.38%

1-Tages-Spanne:

$12.12

$12.98

1-Wochen-Bereich:

$12.12

$13.80

52-Wochen-Spanne:

$12.06

$25.07

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Firmenname

Syndax Pharmaceuticals Inc

Sektor

Healthcare (1164)

Branche

Biotechnology (681)

Telefon

781-419-1400

Adresse

35 GATEHOUSE DRIVE, WALTHAM, MA

Mitarbeiter

Twitter

@syndax

Nächster Verdiensttermin

2025-03-03

Neueste SEC-Einreichungen

SNDX's Discussions on Twitter

Vergleichen Sie SNDX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SNDX Syndax Pharmaceuticals Inc	12.29	1.18B	139.71M	-209.36M	-160.60M	-2.96
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-06-28	Eingeleitet	Jefferies	Buy
2024-01-31	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2023-12-22	Eingeleitet	Mizuho	Buy
2023-10-25	Eingeleitet	BofA Securities	Buy
2023-10-11	Eingeleitet	Goldman	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Outperform
2023-07-11	Eingeleitet	Guggenheim	Buy
2023-04-17	Fortgesetzt	BTIG Research	Buy
2023-01-31	Eingeleitet	Stifel	Buy
2023-01-03	Eingeleitet	JP Morgan	Overweight
2022-07-28	Fortgesetzt	B. Riley Securities	Buy
2022-04-11	Eingeleitet	H.C. Wainwright	Buy
2022-02-15	Eingeleitet	Goldman	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-05-25	Eingeleitet	Citigroup	Buy
2021-02-18	Eingeleitet	B. Riley Securities	Buy
2020-12-03	Eingeleitet	Stifel	Buy
2020-05-22	Hochstufung	Citigroup	Neutral → Buy
2020-05-22	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-18	Herabstufung	Citigroup	Buy → Neutral
2020-05-11	Bestätigt	H.C. Wainwright	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Bestätigt	H.C. Wainwright	Buy
2019-03-08	Bestätigt	H.C. Wainwright	Buy
2019-01-04	Eingeleitet	Robert W. Baird	Outperform
2018-01-05	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-03-16	Eingeleitet	FBR & Co.	Outperform
2017-03-02	Eingeleitet	Instinet	Buy
2016-10-07	Eingeleitet	Guggenheim	Buy
2016-03-28	Eingeleitet	Citigroup	Buy
2016-03-28	Eingeleitet	JMP Securities	Mkt Outperform
2016-03-28	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten

Mar 27, 2025

Simplify Asset Management Inc. Purchases 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Mar 27, 2025

Mar 25, 2025

What Do Analysts Think About Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Future? - Stocks Register

Mar 25, 2025

Mar 24, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $41.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Mar 24, 2025

Mar 23, 2025

Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com

Mar 23, 2025

Charles Schwab Investment Management Inc. Purchases 8,876 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Mar 23, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 5.5% Following Analyst Upgrade - MarketBeat

Mar 23, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00 - Defense World

Mar 23, 2025

Mar 22, 2025

Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com - Investing.com UK

Mar 22, 2025

Mar 21, 2025

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth - Benzinga

Mar 21, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.5% on Analyst Upgrade - Defense World

Mar 21, 2025

Bank of New York Mellon Corp Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Mar 21, 2025

Mar 18, 2025

US Bancorp DE Reduces Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Mar 18, 2025

Mar 17, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.00 Average Price Target from Analysts - MarketBeat

Mar 17, 2025

Mar 13, 2025

Syndax at Barclays Healthcare Conference: Strategic Vision for Menin Inhibitors - Investing.com UK

Mar 13, 2025

Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles - Investing.com India

Mar 13, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio - The Globe and Mail

Mar 12, 2025

Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Mar 12, 2025

Mar 11, 2025

What Does Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Future Hold? - Stocks Register

Mar 11, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% Following Weak Earnings - MarketBeat

Mar 09, 2025

Mar 08, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Mar 08, 2025

Citigroup Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Mar 08, 2025

Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 08, 2025

Syndax Pharmaceuticals Reports 2024 Financial Results - MSN

Mar 08, 2025

Mar 07, 2025

Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

What is B. Riley’s Estimate for SNDX Q3 Earnings? - Defense World

Mar 07, 2025

What is HC Wainwright’s Forecast for SNDX FY2025 Earnings? - Defense World

Mar 07, 2025

Mar 06, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results - MarketBeat

Mar 06, 2025

Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth - TipRanks

Mar 06, 2025

HC Wainwright Reiterates “Buy” Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World

Mar 06, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World

Mar 06, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Mar 06, 2025

Syndax Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025

What is B. Riley’s Forecast for SNDX Q1 Earnings? - Defense World

Mar 06, 2025

What is HC Wainwright’s Forecast for SNDX Q1 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025